Bull Hedging
  • Politics
  • Stocks
  • Business
  • Investing
  • Politics
  • Stocks
  • Business
  • Investing

Bull Hedging

Politics

Senate committee advances nomination of Dr Oz to run Centers for Medicare and Medicaid Services

by admin March 26, 2025
March 26, 2025
Senate committee advances nomination of Dr Oz to run Centers for Medicare and Medicaid Services

The Senate Committee on Finance voted along party lines Tuesday afternoon to advance Dr. Mehmet Oz, President Donald Trump’s pick to lead the Centers for Medicare and Medicaid Services, to a full confirmation vote. 

The party-line vote, which saw 14 GOP senators vote in favor of Oz’s nomination and 13 Democrats vote against it, follows two hearings by the Senate Finance Committee that probed Oz over his plans for the federal healthcare programs, his views on abortion, potential conflicts of interest in the healthcare industry and more.

‘Dr. Oz has years of experience as an acclaimed physician and public health advocate. His background makes him uniquely qualified for this role, and there is no doubt that he will work tirelessly to deliver much-needed change at CMS,’ Sen. Mike Crapo, R-Idaho, the chairman of the committee, said Tuesday. 

Oz graduated from Harvard University and received medical and business degrees from the University of Pennsylvania. He is a former heart surgeon who saw his fame rise through his appearances on daytime TV and 13 seasons of ‘The Dr Oz Show.’

Oz later transitioned into politics, launching an unsuccessful bid for Pennsylvania’s open Senate seat in 2022. He ultimately lost to John Fetterman, then the state’s lieutenant governor. 

If confirmed by the full Senate, Oz would be in charge of nearly $1.5 trillion in federal healthcare spending. Medicare, a federal healthcare program for seniors aged 65 and up, currently provides coverage for about 65 million Americans, according to the Center for Medicare Advocacy. Medicaid, which assists people with low incomes, covers roughly 72 million Americans, according to Medicaid.gov.

Oz’s leadership would direct decisions related to how the government covers procedures, hospital stays and medication within the federal healthcare programs, as well as the reimbursement rates at which healthcare providers get paid for their services.

Earlier this month, Trump’s pick to lead the NIH and FDA, Dr. Jay Bhattacharya and Dr. Marty Makary, respectively, were also approved in committee and are awaiting full confirmation votes in the Senate scheduled for later Tuesday. It is unclear when Oz’s full Senate vote will take place.

Around the same time that Bhattacharya and Makary won committee approval, Trump withdrew his nomination of former Florida Rep. David Weldon to run the CDC, over fears he did not have the GOP support to clear full confirmation. On Monday, the Trump administration named Susan Monarez, acting director of the CDC, as its new nominee.

This post appeared first on FOX NEWS

previous post
Trump orders FBI to declassify documents from ‘Crossfire Hurricane’ Russia investigation
next post
Biden-era guidance encouraged use of Signal app by highly-targeted govt officials: ‘Best practice’

Related Posts

Trump denounces court’s ‘political’ tariff decision, calls on...

May 30, 2025

Banned chemicals found in American shampoo, sunscreen and...

August 1, 2025

Trump’s unpredictable Middle East moves actually follow a...

June 20, 2025

CDC official includes ‘pregnant people’ terminology and pronouns...

August 29, 2025

DAVID MARCUS: The 3 issues driving far-left’s split...

November 13, 2025

NATO chief says upcoming Trump-Putin meeting will be...

August 11, 2025

‘Dead of night’: Dems accuse GOP of cowardice...

May 20, 2025

World Press Freedom Day: Release my father Jimmy...

May 4, 2025

Grieving parents of American terror victim plead with...

July 26, 2025

Fetterman: Those hoping Trump fails are ‘rooting against...

December 23, 2024

Recent Posts

  • The Real Drivers of This Market: AI, Semis & Robotics
  • S&P 500 Breaking Out Again: What This Means for Your Portfolio
  • Republican populism craters as Trump stumbles, Democrats surge
  • Trump admin warned to take front seat as UN chief race shifts left, boosting anti-US contenders
  • GOP unveils plan for ‘Trump Health Freedom Accounts’ to replace Obamacare subsidies with state waivers

Recent Comments

No comments to show.

About Us

About Us

Design Magazine

Welcome to Design Magazine. Follow us for daily & updated design tips, guide and knowledge.

Stay Connect

Facebook Twitter Instagram Pinterest Youtube Email

Recent Posts

  • The Real Drivers of This Market: AI, Semis & Robotics

    December 6, 2025
  • S&P 500 Breaking Out Again: What This Means for Your Portfolio

    December 6, 2025
  • Republican populism craters as Trump stumbles, Democrats surge

    December 6, 2025
  • Trump admin warned to take front seat as UN chief race shifts left, boosting anti-US contenders

    December 6, 2025
  • GOP unveils plan for ‘Trump Health Freedom Accounts’ to replace Obamacare subsidies with state waivers

    December 6, 2025
  • Abortion restrictions create major roadblock for bipartisan Obamacare subsidy deal in Senate

    December 6, 2025

Editors’ Picks

  • 1

    Small Caps are Set to Skyrocket in 2025—Here’s What You Need to Know

    December 12, 2024
  • 2

    Environmental Approval for Boland Infield Studies & Update on Scaled Column ISR Test

    September 19, 2025
  • 3

    Ad revenue should stabilize for media companies in 2025 — if they have sports

    December 31, 2024
  • 4

    Trump leaves China guessing what his next move is with unusual inauguration invitation

    December 15, 2024
  • 5

    Zinc Stocks: 4 Biggest Canadian Companies in 2025

    January 15, 2025
  • 6

    Lead Price Forecast: Top Trends for Lead in 2025

    January 11, 2025
  • 7

    Uranium Price Forecast: Top Trends That Will Affect Uranium in 2025

    December 19, 2024
Promotion Image

banner

Categories

  • Business (602)
  • Investing (2,582)
  • Politics (3,117)
  • Stocks (946)
  • About us
  • Contacts
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Disclaimer: bullhedging.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2025 bullhedging.com | All Rights Reserved